The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|February 7, 2020
Emerson Launches VR-Based Training Program
Author(s)Pharmaceutical Technology Editors
The program supports Emerson’s digital transformation initiative which encourages employees to learn at a faster pace through immersive experiences that enhance safety and overall operational performance.
Advertisement
Emerson announced the launch of Mimic Field 3D, a virtual reality (VR) training program aimed at helping new and incoming workers understand how changes in the field impact industrial plant processes.
As an alternative to training on physical equipment, the new program gives personnel simulated, hands-on experience to prepare for potential operating changes and hazardous plant areas, according to a Feb. 6, 2020 company press release. The VR program allows employees to learn at a faster pace through immersive experiences that enhance safety and overall operational performance.
“Emerson’s digital twin portfolio is changing how we prepare the future workforce. Our industry will become increasingly reliant on VR tools like these to address the growing skills gap and improve training effectiveness,” said Jim Nyquist, group president of systems and solutions at Emerson, in the press release. “This advanced technology enhances training by offering a hands-on experience, which ultimately improves the safety of workers.”
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement